| WARRANTS AND OPTIONS |
NOTE
19 – WARRANTS AND OPTIONS:
a)
Warrants
| |
(i) |
Warrant
transactions for the years ended December 31, 2025, and 2024 are as follows: |
SCHEDULE OF WARRANTS TRANSACTIONS
| | |
Number | | |
Weighted Average Exercise Price | |
| Balance, January 1, 2024 | |
| 4,386,234 | | |
$ | 6.58 | |
| Warrants issued in the January 2024 Registered Direct Offering | |
| 651,062 | | |
| | |
| Warrants issued in the July 2024 Private Placement | |
| 1,200,000 | | |
| | |
| Exercise of warrants | |
| (1,330,300 | ) | |
| | |
| Warrants issued in the October 2024 Private Placement | |
| 21,333 | | |
| | |
| Balance, December 31, 2024 | |
| 4,928,329 | | |
$ | 6.17 | |
| Expiry of warrants | |
| (721,239 | ) | |
| | |
| Exercise of warrants | |
| (3,474,595 | ) | |
| | |
| Warrants issued in the January 2025 Registered Direct Offering and September 2025 underwritten public offering | |
| 554,313 | | |
| | |
| Balance, December 31, 2025 | |
| 1,286,808 | | |
$ | 13.39 | |
| |
(ii) |
As
of December 31, 2025, the Company had outstanding warrants, enabling the holders to acquire common shares as follows: |
SCHEDULE OF OUTSTANDING WARRANTS
December 31, 2025 | | |
Expiry date | |
Exercise price | | |
Exercise price (USD) | |
| | 88,440 | | |
April 18, 2026 | |
ILS | 72.563 | | |
$ | 22.75 | |
| | 433,825 | | |
May 28, 2026 | |
ILS | 72.563 | | |
$ | 22.75 | |
| | (*) 252,967 | | |
January 4, 2026 | |
CAD | 5.13 | | |
$ | 3.75 | |
| | 3,200 | | |
October 2, 2026 | |
CAD | 2.70 | | |
$ | 1.88 | |
| | 183,751 | | |
January 29, 2030 | |
USD | 8.00 | | |
$ | 8.00 | |
| | 324,625 | | |
September 16, 2030 | |
USD | 10.00 | | |
$ | 10.00 | |
| | 1,286,808 | | |
| |
| | | |
| | |
| (*) | Liability Warrants
– see note 16. |
A2Z
CUST2MATE SOLUTIONS CORP.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Expressed
in Thousands of US Dollars, except per share data)
NOTE
19 – WARRANTS AND OPTIONS (CONTINUED):
b)
Stock Options
Stock
option transactions for the years ended December 31, 2025, and 2024 are as follows:
SCHEDULE OF STOCK OPTION TRANSACTIONS
| | |
Number | | |
Weighted Average Exercise Price (CAD) | | |
Weighted Average Exercise Price (USD) | |
| Balance January 1, 2024 | |
| 1,411,170 | | |
$ | 6.33 | | |
$ | 4.78 | |
| Options granted (i) | |
| 552,000 | | |
| | | |
| | |
| Options cancelled | |
| - | ) | |
| | | |
| | |
| Options exercised | |
| - | ) | |
| | | |
| | |
| Expiry of options | |
| (206,500 | ) | |
| | | |
| | |
| Balance December 31, 2024 | |
| 1,756,670 | | |
$ | 5.39 | | |
$ | 3.75 | |
| Options cancelled | |
| (127,668 | ) | |
| | | |
| | |
| Options exercised | |
| (225,332 | ) | |
| | | |
| | |
| Options granted (ii)(iii)(iiii)(iv) | |
| 2,863,500 | | |
| | | |
| | |
| Balance December 31, 2025 | |
| 4,267,170 | | |
$ | 6.14 | | |
$ | 8.41 | |
| (i) |
On
August 14, 2024, 552,000 stock options were issued to employees, consultants and officers with an exercise price of $1.78. The options
expire on August 13, 2029. The fair value of the options granted was estimated at $779 using the Black-Scholes option pricing model,
using the following assumptions: Share Price: $1.78; Expected option life 5 years; Volatility 109%; Risk-free interest rate 3.67%;
Dividend yield 0%. |
| |
|
| (ii) |
On
January 15, 2025, the Company granted an employee 105,000 share options to purchase Common Shares of the company with an exercise
price of $6.40 per share. The share options vest quarterly starting on January 15, 2026, and expire on January 15, 2035. The fair
value of the options granted was estimated at $627 using the Black-Scholes option pricing model, using the following assumptions:
Share Price: $6.38; Expected option life 10 years; Volatility 110%; Risk-free interest rate 4.65%; Dividend yield 0%. |
| |
|
| (iii) |
On
February 12, 2025, the Company granted the CEO 500,000 share options to purchase Common Shares with an exercise price of $6.40 per
share, vesting immediately and expiring on February 2, 2035. The fair value of the options granted was estimated at $3,092 using
the Black-Scholes option pricing model, using the following assumptions: Share Price: $6.61; Expected option life 10 years; Volatility
110%; Risk-free interest rate 4.64%; Dividend yield 0%. |
| |
|
| (iii) |
On
June 20, 2025, 229,000 share options were granted to employees. 30,000 share options have an exercise price of $1.775 per share and their
vesting schedule is as follows: a third vest on June 30, 2025, a third on June 30, 2026, and a third on June 30, 2027. The remaining
199,000 share options have an exercise price of $6.40 per share and their vesting schedule is as follows: a third vest on June 30, 2026,
a third on June 30, 2027, and a third on June 30, 2028. The options expire on June 20, 2035. The fair value of the options granted was
estimated at $2,252 using the Black-Scholes option pricing model, using the following assumptions: Share Price: $10.36; Expected option
life 10 years; Volatility 108%; Risk-free interest rate 4.38%; Dividend yield 0%. |
| |
|
| (iv) |
On
October 9, 2025, 239,000 share options were granted to employees. 215,000 share options have an exercise price of $8.00 per share, 24,000
share options have an exercise price of $6.40 per share. The vesting schedule is as follows: a third vest on September 30, 2026, a third
on September 30, 2027, and a third on September 30, 2028. The options expire on October 9, 2035. The fair value of the options granted
was estimated at $1,644 using the Black-Scholes option pricing model, using the following assumptions: Share Price: $7.33; Expected option
life 10 years; Volatility 113%; Risk-free interest rate 4.15%; Dividend yield 0%. |
| |
|
| (iv) |
On
December 30, 2025, 1,790,500 share options were granted to employees. 474,500 share options have an exercise price of $8.00 per share
and their vesting schedule is as follows: a third vest on December 30, 2025, a third on December 30, 2027, and a third on December
30, 2028. 800,000 share options have an exercise price of $8.00 per share and vest immediately. 1,000 share options have an exercise
price of $6.40 per share and their vesting schedule is as follows: a third vest on June 30, 2026, a third on June 30, 2027, and a
third on June 30, 2028. 15,000 share options have an exercise price of $8.00 per share and their vesting schedule is as follows:
a third vest immediately, a third on December 30, 2026, and a third on December 30, 2027. The remaining 500,000 share options have
an exercise price of $6.00 per share and vest immediately. The options expire on December 30, 2035. The fair value of the options
granted was estimated at $7,747 using the Black-Scholes option pricing model, using the following assumptions: Share Price: $6.43;
Expected option life 10 years; Volatility 105%; Risk-free interest rate 4.13%; Dividend yield 0%. |
A2Z
CUST2MATE SOLUTIONS CORP.
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Expressed
in Thousands of US Dollars, except per share data)
NOTE
19 – WARRANTS AND OPTIONS (CONTINUED):
b)
Stock Options (continued)
| |
(vi) |
As
of December 31, 2025, the Company had outstanding stock options, enabling the holders to acquire common shares as follows: |
SCHEDULE
OF OUTSTANDING STOCK OPTIONS
Outstanding as of December 31, 2025 | | |
Exercisable as of December 31, 2025 | | |
Expiry date | |
Exercise price (CAD) | | |
Exercise price (USD) | |
| | 20,000 | | |
| 20,000 | | |
June 3, 2026 | |
CAD | 21.00 | | |
$ | 15.32 | |
| | 6,670 | | |
| 6,670 | | |
October 28, 2026 | |
CAD | 20.00 | | |
$ | 14.59 | |
| | 360,000 | | |
| 360,000 | | |
August 2, 2032 | |
CAD | 8.90 | | |
$ | 6.49 | |
| | 120,000 | | |
| 120,000 | | |
August 21, 2032 | |
CAD | 10.00 | | |
$ | 7.30 | |
| | 220,000 | | |
| 220,000 | | |
January 4, 2033 | |
CAD | 4.13 | | |
$ | 3.01 | |
| | 100,000 | | |
| 100,000 | | |
January 4, 2033 | |
CAD | 4.13 | | |
$ | 3.01 | |
| | 40,000 | | |
| 40,000 | | |
November 25, 2027 | |
CAD | 5.03 | | |
$ | 3.67 | |
| | 103,000 | | |
| 91,000 | | |
April 18, 2033 | |
CAD | 4.00 | | |
$ | 2.92 | |
| | 441,000 | | |
| 146,333 | | |
August 14, 2034 | |
CAD | 2.43 | | |
$ | 1.78 | |
| | 105,000 | | |
| - | | |
January 15, 2035 | |
CAD | 8.77 | | |
$ | 6.40 | |
| | 500,000 | | |
| 500,000 | | |
February 2, 2035 | |
CAD | 8.77 | | |
$ | 6.40 | |
| | 30,000 | | |
| 10,000 | | |
June 20, 2035 | |
CAD | 2.43 | | |
$ | 1.775 | |
| | 192,000 | | |
| - | | |
June 20, 2035 | |
CAD | 8.77 | | |
$ | 6.40 | |
| | 239,000 | | |
| 6,667 | | |
October 9, 2035 | |
CAD | 10.96 | | |
$ | 8.00 | |
| | 500,000 | | |
| 500,000 | | |
December 30, 2035 | |
CAD | 8.22 | | |
$ | 6.00 | |
| | 1,290,500 | | |
| 805,000 | | |
December 30, 2035 | |
CAD | 10.96 | | |
$ | 8.00 | |
| | 4,267,170 | | |
| 2,925,670 | | |
| |
| | | |
| | |
| |
(vii) |
Share-based
compensation expense is recognized over the vesting period of options. During the year ended December 31, 2025, share-based compensation
of $12,703 was recognized and charged to the Consolidated Statement of Comprehensive Loss (December 31, 2024 - $729, December 31,
2023 – $4,245). |
c)
RSU’s
On
January 4, 2023, the Company granted 410,800 RSUs to directors, officers and advisers, of which 104,000 RSUs are to executives and directors,
pursuant to the Company’s RSU Plan and in acknowledgment of the Company’s management recent success and increased future
workload. The RSUs will vest at each recipient’s discretion and taking into account personal tax implications and convert into
410,800 common shares of no-par value in the Company.
On
April 18, 2023, the Company granted 46,500 RSUs to employees, pursuant to the Company’s RSU Plan. The RSUs will vest at each recipient’s
discretion and taking into account personal tax implications and convert into 46,500 common shares of no-par value in the Company.
On
June 28, 2023, the Company granted 66,000 Restricted Share Units (“RSUs”) to officers pursuant to the Company’s RSU
Plan. The RSUs will vest at each recipient’s discretion and taking into account personal tax implications and convert into 66,000
common shares of no-par value in the Company (“Common Shares”).
On
August 14, 2024, the Company granted 326,000 Restricted Share Units (“RSUs”) to officers and advisors, pursuant to the Company’s
RSU Plan. The RSUs will vest at each recipient’s discretion and taking into account personal tax implications and convert into
326,000 common shares of no-par value in the Company.
On
January 15, 2025, the Company granted an employee 20,000 Restricted Share Units (“RSUs”) pursuant to the Company’s
RSU plan and in acknowledgement of the Company’s recent success and future workload. The RSUs will vest immediately.
On
February 12, 2025, the Company granted the CEO 400,000 RSUs pursuant to the Company’s RSU plan and in acknowledgement of the Company’s
recent success and future workload. The RSUs will vest upon the Company entering into one or more agreements for the binding supply of
at least 10,000 smart carts.
On
June 20, 2025, the Company granted 125,000 RSUs to an advisor. The RSUs vest immediately.
On
December 28, 2025, the Company granted the CEO 500,000 RSUs pursuant to the Company’s RSU plan and in acknowledgement of the Company’s
recent success and future workload. The RSUs will vest upon the Company entering into one or more agreements for the binding supply of
at least 30,000 smart carts.
On
December 30, 2025, the Company granted 500,000 RSUs to an advisor. The RSUs vest immediately.
RSU’s
transactions for the year ended December 31, 2025, and for the year ended December 31, 2024, are as follows:
SCHEDULE
OF RSU’S TRANSACTIONS
| | |
Number | |
| Balance, January 1, 2024 | |
| 588,834 | |
| RSUs granted | |
| 326,000 | |
| Expiry of RSUs | |
| (40,166 | ) |
| Exercise of RSUs | |
| (764,001 | ) |
| Balance, December 31, 2024 | |
| 110,667 | |
| RSUs granted | |
| 1,545,000 | |
| Expiry of RSUs | |
| (6,000 | ) |
| Exercise of RSUs | |
| (219,667 | ) |
| Balance, December 31, 2025 | |
| 1,430,000 | |
Total
exercisable RSU’s as at December 31, 2025, are 930,000. During the year ended December 31, 2025, share-based compensation in respect
of RSU’s of $7,619 was charged to the Consolidated Statement of Comprehensive Loss (December 31, 2024 – $1,184, December
31, 2023 – $1,079).
|